CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 298 enrolled
Drug / intervention
2 mg IV hydromorphonedrug
Likely dose
2 mg IV hydromorphonefrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00305110
NCT00305110Phase 2Completed
CompareCT.gov

Safety and Speed of Onset of a Fixed Dose of Intravenous Hydromorphone in the Treatment of Adult Patients Presenting to the Emergency Department With Acute Severe Pain

Montefiore Medical Center·interventional·Posted Mar 21, 2006·Updated Aug 20, 2018

In Brief

A Phase 2 clinical trial evaluating 2 mg IV hydromorphone for Acute Pain. Completed, enrolled 298 participants across 1 site.

Detailed Summary

The purpose of this study is to determine the safety and speed of onset of 2mg intravenous hydromorphone (Dilaudid) in patients weighing at least 150 lbs presenting to the emergency department with acute severe pain

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Pain
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 21, 2006
Enrollment StartJan 1, 2006
Primary CompletionOct 1, 2006
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 20.3 years ago

Interventions

2 mg IV hydromorphonedrug